



Co-funded by the
European Union

Grant Agreement Number: 101202831

Project Title: European Vaccines Hub for Pandemic Readiness

Project Acronym: EVH

EU4Health Programme

Deliverable: D2.1 - Presentation of EVH project in the Participant websites and social media

"Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them."

Document overview

Deliverable number	D2.1
Deliverable name	Presentation of EVH project in the Participant websites and social media
Work package number / name	2 / Dissemination, Communication, Training and stakeholder engagement
Task number / name	T2.1 / Dissemination & communication activities (M1-M48)
Due date	31 May 2025
Dissemination level	PU
Authors	Luisa Borgianni (SVA) Tiziana Spadafina (SVA)
Lead Beneficiary	Sclavo Vaccines Association - SVA
Project website	www.europeanvaccineshub.eu (under development)

Table of content

Document overview.....	2
1. Summary	3
2. European Vaccine Hub (EVH) Project Overview	3
3. Presentation of EVH project on the Participant websites.....	3
4. Presentation of EVH project in the social media	9
5. Project leaflet.....	11
6. Conclusion	12

1. Summary

In the contest of WP2 - Dissemination, Communication, Training and stakeholder engagement led by SVA, the Deliverable D2.1 “Presentation of EVH project in the Participant websites and social media” is a public report on the communication of EVH project in the participant websites, social media and project leaflet, due by SVA at month 3.

2. European Vaccine Hub (EVH) Project Overview

The European Vaccine Hub (EVH) project aims to establish a comprehensive European-wide hub dedicated to public-health–relevant vaccine development. This initiative will integrate excellence in vaccine and human monoclonal antibodies development with clinical trials and scalable manufacturing activities. The project will contribute to the creation of pandemic-prototype vaccines and scalable technologies through a consortium of major EU Vaccine R&D institutions and manufacturers, ensuring effective coordination of national vaccine research programs.

Aligned with the current international consensus on pandemic-vaccine development, the EVH will leverage insights from existing prototypes to facilitate the rapid selection and deployment of the most suitable vaccine candidates during emerging pandemics. The EVH will not only establish a reactive R&D system and knowledge hub linking leading research institutions but also develop relevant processes and procedures by initiating vaccine-development projects within its framework.

The focus will be on a select group of pathogens with immediate relevance to pandemic preparedness, as identified in the recently issued WHO Pathogens Prioritization report for the European region. From prototype design to clinical applications, EVH’s efforts will accelerate innovations, enhance clinical evaluation capacities, and coordinate with manufacturers. Additionally, the project aims to optimize the digitalization of design and distribution processes, thereby advancing the overall efficiency and effectiveness of vaccine development and deployment.

3. Presentation of EVH project on the Participant websites

The EVH project has been successfully presented on both the coordinator’s and the participant websites, ensuring broader visibility and engagement among specialized audience and stakeholders. Additionally, the EVH project has been prominently featured on participants' social media pages, further enhancing its visibility and accessibility to a wider audience. English has been the preferred language for communication. These efforts ensure easy access to relevant information, fostering engagement and collaboration. By leveraging digital platforms, the project reaches a broader community, promoting its objectives and encouraging participation.

Examples of EVH presentation are showed below.

European Vaccines Hub (EVH) for

https://www.izsvenezie.it/european-vaccines-hub-pandemic-readiness/

Home » European Vaccines Hub (EVH) for Pandemic Readiness, una nuova partnership europea per lo sviluppo di vaccini



European Vaccines Hub (EVH) for Pandemic Readiness, una nuova partnership europea per lo sviluppo di vaccini

28 Maggio 2023 | In prima plana, Ricerche & Attività, IZS-V | Ricerca e innovazione, IZS-V | Virologia speciale e sperimentazione

[In](#) [Share](#) [Facebook](#) [Twitter](#) [LinkedIn](#) [WhatsApp](#) [Telegram](#)

L'Istituto Zooprofilattico Sperimentale delle Venezie (IZSVe) supporterà il nascente Hub europeo nello sviluppo e nella valutazione di vaccini e anticorpi monoclonali contro patogeni dal potenziale pandemico.

L'Autorità per la preparazione e la risposta alle emergenze sanitarie (HERA) della Commissione Europea, attraverso l'Agenzia esecutiva europea per la salute e il digitale (EDRA), sostiene la creazione del **European Vaccines Hub (EVH) for Pandemic Readiness**, un centro paneuropeo dedicato al progresso nello sviluppo di vaccini rilevanti per la salute pubblica. L'accordo di finanziamento è stato firmato giovedì 22 maggio e rappresenta un passo avanti nello sviluppo dei vaccini rilevanti per la salute pubblica. Integrando l'ecosistema nella ricerca sui vaccini, nello sviluppo di anticorpi monoclonali umani (mAb), negli studi clinici e nelle attività di produzione su larga scala, EVH crea un ambiente europeo dinamico e collaborativo.

Il consorzio EVH è composto da 11 enti beneficiari e 13 affiliati e associati, provenienti da 7 diversi Paesi, tra cui importanti organizzazioni europee direttamente coinvolte nello sviluppo di vaccini e responsabili della preparazione pandemica nei rispettivi Stati. Il progetto è coordinato dalla Scienza Vaccines Association, un'organizzazione no-profit con sede a Siena impegnata nel sostegno alla ricerca e allo sviluppo vaccinale.

Il progetto EVH contribuisce allo sviluppo di vaccini prototipo per le pandemie e di tecnologie scalabili, attraverso un consorzio di importanti istituti europei di ricerca e sviluppo e di impianti produttivi farmaceutici, garantendo il coordinamento dei programmi nazionali di ricerca sui vaccini. L'EVH ispira ad una visione largamente condivisa a livello internazionale, secondo la quale lo sviluppo di vaccini pandemici non può prescindere da una fase preliminare di sviluppo di prototipi, che consenta una rapida selezione e distribuzione di vaccini specifici per patogeni emergenti nel corso di emergenze epidemiche o pandemiche.

Strutturato su quattro pilastri a supporto delle principali attività e infrastrutture della pipeline di sviluppo vaccinale, EVH integra istituzioni europee leader con competenze distinte e incarichi specifici di preparazione pandemica. In dettaglio: l'Europa 1 "Discovery", guidato dalla Fondazione



IZSVe Mailing List

Grazie alla mailing list puoi rimanere aggiornato sulle attività dell'Istituto, i corsi e gli eventi organizzati, i servizi offerti.

[Iscriviti](#)

Categorie news

- In prima plana
- Ricerche & Attività
- Sorveglianza & Prevenzione
- Servizi & Qualità
- Formazione & Eventi
- Comunicazione & Media
- Istituto & Amministrazione

News per temi

- Animali e settori
- Alimenti sicuri
- Biosicurezza animale
- Relazione uomo-animalità
- Malattie e patogeni A
- Malattie e patogeni Q
- Malattie e patogeni P 2
- Sostanze e contaminanti
- Tecnologia e innovazione
- Altri temi

News per strutture

- Direzione generale e amministrazione
- Strutture sanitarie
- Sezioni territoriali
- Centri specializzati
- Centri di riferimento

Projects - Scivo Vaccines Associ

Launch of the European Vaccines

https://www.dzif.de/en/launch-european-vaccines-hub-pandemic-readiness-new-european-public-private-partnership-public

DZIF

RESEARCH TRANSLATION DZIF ACADEMY NEWSROOM ABOUT US DE EN

May 23 2025 – Press Release

Launch of the European Vaccines Hub for Pandemic Readiness, a new European public-private partnership for public health-relevant vaccine development

Top researchers from the German Center for Infection Research play key role in major European vaccine project

HOME » LAUNCH OF THE EUROPEAN VACCINES HUB FOR PANDEMIC READINESS: A NEW EUROPEAN PUBLIC-PRIVATE PARTNERSHIP FOR PUBLIC HEALTH-RELEVANT VACCINE DEVELOPMENT



Key staff meeting of the European Vaccines Hub for Pandemic Readiness (EVH) on 22 May 2025, Berlin, Germany. Credit: DZIF

For staff meeting of the European Vaccines Hub for Pandemic Readiness (EVH) on 22 May 2025, Berlin, Germany. Credit: DZIF

© Scivo Vaccines Association

The Health Emergency Preparedness and Response Authority (HERA) of the European Commission, through the European Health and Digital Executive Agency (HaDEA) supports the establishment of the "European Vaccines Hub for Pandemic Readiness (EVH)", a pan-European center dedicated to advancing public health-relevant vaccine development. The Grant Agreement has been signed today, marking a transformative step in public-health-relevant vaccine development.

Contact person

Dr. Nicola Vitale
German Center for Infection Research
Public Relations Officer
[SEND MAIL](#)

We collect and process your personal information using cookies for the following purposes: Content Management System (CMS) and user statistics. For detailed information, please see our privacy policy.

[Privacy](#) [Cookies](#)

By integrating excellence in vaccine research, human

Projects - Sclavo Vaccines Associ... Launch of the European Vaccines Hub for Pandemic Readiness - new European public-private partnership-public

https://www.pasteur.fr/en/press-area/press-documents/launch-european-vaccines-hub-pandemic-readiness-new-european-public-private-partnership-public

RESEARCH EDUCATION INTERNATIONAL PUBLIC HEALTH INNOVATION CAREERS CERIS DONATE FR

INSTITUT Pasteur THE INSTITUT PASTEUR OUR MISSIONS SUPPORT US MEDICAL CENTER THE RESEARCH JOURNAL PRESS AREA

PRESS DOCUMENTS RESOURCES FOR MEDIAS

Home > Press area > Press documents > Launch of the European Vaccines Hub for Pandemic Readiness, a new European public-private partnership for public health-relevant vaccine development

LAUNCH OF THE EUROPEAN VACCINES HUB FOR PANDEMIC READINESS, A NEW EUROPEAN PUBLIC-PRIVATE PARTNERSHIP FOR PUBLIC HEALTH-RELEVANT VACCINE DEVELOPMENT

PRESS RELEASE | 2025.05.23

Print | Share | LinkedIn | Facebook

The Health Emergency Preparedness and Response Authority (HERA) of the European Commission, through the European Health and Digital Executive Agency (HaDEA) supports the establishment of the "European Vaccines Hub (EVH) for Pandemic Readiness", a pan-European center dedicated to advancing public-health-relevant vaccine development. The Grant Agreement has been signed today, marking a transformative step in public-health-relevant vaccine development.

By integrating excellence in vaccine research, human monoclonal antibody (H-mAbs) development, clinical trials, and scalable manufacturing activities, EVH creates a dynamic and collaborative European environment.

The EVH consortium is made up of 11 Beneficiaries, 13 Affiliated and Associated entities, from 7 different countries, including leading EU organizations directly involved in vaccine development and in charge of pandemic preparedness in their own countries. The EVH project is coordinated by the "Sclavo Vaccines Association", a non-profit organization based in Siena devoted to support vaccine research and development.

Projects - Sclavo Vaccines Associ... uantwerpen evh - Google Search... UAntwerpen lanceert mee Europe...

https://cartoon-productions.be/uantwerpen-lanceert-mee-european-vaccines-hub-for-pandemic-readiness/

woensdag, juni 25, 2025 Zoeken... Login

HOME - BOEKEN - CULTUUR - FILM - GASTRONOMIE - TOEGANG

UA Antwerpen lanceert mee European Vaccines Hub for Pandemic Readiness

Mai 24, 2025 - Marina Couvets



Consortium zal zich toelagen op de ontwikkeling van vaccins

In het Italiaanse Siena werd de European Vaccines Hub (EVH) for Pandemic Readiness boven de doopvont gehouden. Dat pan-Europese centrum zal zich toelagen op de ontwikkeling van vaccins. UAntwerpen is een van de belangrijkste partners van het project, waar de komende vier jaar 170 miljoen euro voor wordt vrijgemaakt.

Elf universiteiten en onderzoeksinstituten maken de kern van het EVH-consortium uit. Dertien andere organisaties en instellingen zijn ook betrokken bij het project. Ze komen uit zeven verschillende Europese landen. Alle partners zijn rechtstreeks betrokken bij de ontwikkeling van vaccins en zijn verantwoordelijk voor pandemievoorbereiding en -respons in hun respectieve landen. De coördinatie ligt bij de Sclavo Vaccines Association, een non-profitorganisatie gevestigd in Siena.

Recente berichten

- A** Versuimde dienstverlening wegens staking op woensdag 25 juni
17 JUNI 2025
- A** Zilvermeyer maakt zich klaar voor 23.000 leerlingen op Perinenzakkenweek
17 JUNI 2025
- A** Dier en Hare, Boedonum koken ditte zomer "Lekker Mosa" op vijand
17 JUNI 2025
- A** Slechtbeheersers in Antwerpen biba helpen studenten tijdens examenperiode
17 JUNI 2025
- A** Port of Antwerp-Bruges start restauratie Oosterweelkijp
17 JUNI 2025
- A** Samson & Marie Kerstshow: Het Feest
17 JUNI 2025
- A** Stad Antwerpen blapt gratis concertbeelden aan voor eigenaren van wereldballeren
17 JUNI 2025
- A** Stichting Kempena Landhuis restaurant poortmuur abdijste Weeromdij
17 JUNI 2025

[Home](#) > [Current events](#) > [News](#) > [Launch of the European Vaccines Hub for Pandemic Readiness](#)

23.05.2025

Launch of the European Vaccines Hub for Pandemic Readiness

New European public-private partnership for public health-relevant vaccine development



Kick-off meeting of the European Vaccines Hub for Pandemic Readiness (EVH) on 22-23 May in Siena, Italy. Coordinated by the Italian NPO Sciavo Vaccines Association, the EVH consortium comprises eleven beneficiaries from seven different countries, including leading EU organizations with national responsibility for pandemic preparedness

The Health Emergency Preparedness and Response Authority (HERA) of the European Commission, through the European Health and Digital Executive Agency (HaDEA) supports the establishment of the "European Vaccines Hub for Pandemic Readiness (EVH)", a pan-European center dedicated to advancing public health-relevant vaccine development. The Grant Agreement has been signed today, marking a transformative step in public-health-relevant vaccine development.

By integrating excellence in vaccine research, human monoclonal antibody (H-mAbs) development, clinical trials, and scalable manufacturing activities, EVH creates a dynamic and collaborative European environment.

The EVH consortium is made up of 11 beneficiaries, 13 affiliated and associated entities, from 7 different countries, including leading EU organizations directly involved in vaccine development and in charge of pandemic preparedness in their own countries. The EVH project is coordinated by the "Sclavo Vaccines Association", a non-profit organization based in Siena devoted to support vaccine research and development.

The EVH project contributes to the development of an agreed set of pandemic-prototype vaccines and scalable technologies through a

université libre de bruxelles euro: x L'ULB est membre de l'European x We are proud to contribute to th: x +

https://www.linkedin.com/posts/epiv-ulg_evh-vaccines-europe-activity-733277664600399872-NHLs

LinkedIn

Articoli Persone Learning Lavoro Giochi Scarica l'app Iscriviti ora Accedi

Post di European Plotkin Institute for Vaccinology - Université libre de Bruxelles

European Plotkin Institute for Vaccinology - Université libre de Bruxelles
709 follower
1 mese · Modificato

We are proud to contribute to the European Vaccines Hub (EVH) for Pandemic Readiness, an ambitious, EU-funded initiative aimed at building a robust ecosystem for public health-relevant #vaccines, from early discovery to clinical evaluation and scalable manufacturing. 🏆

As part of this effort, the European Plotkin Institute for Vaccinology - Université libre de Bruxelles at the ULB and Vaccinopolis at the University of Antwerp will coordinate EVH's clinical research and laboratory activities, establishing common standards for vaccine assessment and promoting collaborative research across Europe.

🏆 Together, we're working to accelerate and coordinate vaccine development in #Europe when it matters most.

Read more at:
📄 <https://lnkd.in/gHtVX6ni>
📄 <https://lnkd.in/gRpm24Cx>

#HERA #EU4Health #HaDEA #PublicHealth #PandemicPreparedness



709 follower
Visualizza profilo + Segui

70 - 3 commenti

Consiglia Commenta Condividi

(1) Feed | LinkedIn x (1) German Center for Infection Research x +

company/deutsches-zentrum-für-infektionsforschung/posts/

in Search

Home My Network Jobs Messaging Notifications Me For Business Try Premium for €0

DZIF German Center for Infection Research ... Following Message

Home About Posts Jobs People

DZIF German Center for Infection Research
8,197 followers
4w · Edited ·

🎉 Launch of the European Vaccines Hub: a new era for pandemic preparedness in Europe

We are proud to announce the launch of the European Vaccines Hub (EVH)—a new EU-funded public-private partnership that will serve as a central platform to strengthen vaccine development across Europe in the long term. As a pan-European center, the EVH will leverage academic research, clinical expertise, and regulatory know-how to strengthen vaccine development across Europe in the long term.

The EVH brings together partners from seven European countries integrating leading European institutions—among them the DZIF—with distinct expertise. The Hub is built on four pillars:

- 🔬 Pillar 1 – Discovery, led by [Fondazione Biotechnopolo di Siena](#)
- 🧪 Pillar 2 – Preclinical Studies, led by [Institut Pasteur](#)
- 🏥 Pillar 3 – Clinical Studies, led by [Vaccinopolis](#)
- 🌱 Pillar 4 – Manufacturing & Regulation, led by the [#DZIF](#)

💡 With a focus on priority pathogens identified by the WHO, EVH will help ensure that Europe is better prepared for future pandemics. "By bringing together top European researchers with a broad network of European and global research institutions, NGOs, public authorities and companies, we hope to make important progress that can sustainably improve the development and manufacturing of pandemic vaccines", says DZIF scientist Professor Dr. [Isabelle Bekeredjjan-Ding](#) from the University of Marburg—a member institution of the DZIF—who, as DZIF coordinator, will be instrumental in managing and coordinating the EU-wide EVH project at the national level.

The DZIF is contributing extensive expertise in vaccine and antibody platforms, preclinical development, immune monitoring, working under high-security conditions (BSL-4), conducting clinical trials, and data management and regulatory support.

"The EVH demonstrates that the DZIF, with its translational research areas and infrastructures, is among the best in Europe. I am delighted that this expertise, pooled at the national level within the DZIF, can be incorporated into a Europe-wide project," says DZIF Executive Board Chair Prof. Dr. [@Dirk Busch](#).

The EVH project is co-funded for the next four years from the European Union's EU4Health programme, with an EU contribution of around 102 million EUR and estimated total project cost of around 170 million EUR. About one-fifth of the EU contribution will go to a group of eight German universities and non-university research institutions under the umbrella of the DZIF.

See who's hiring on LinkedIn.


About Accessibility Help Center
Privacy & Terms Ad Choices
Advertising Business Services
Get the LinkedIn app More

LinkedIn LinkedIn Corporation © 2025


4. Presentation of EVH project in the social media

The project's social media accounts were established by the coordinator, Sclavo Vaccines Association, three months after the project's starting date, in collaboration with other international initiatives. English has been the preferred language for communication.

To reach a broad audience and present EVH in an informal and accessible manner, a **Bluesky account (@evhproject.bsky.social)** was created and it is showed below.



Additionally, to engage a more specialized audience, a **LinkedIn page dedicated to EVH** was set up. Below the screenshot of the EVH LinkedIn page.



Project hashtags, #Europeanvaccineshub and #EVHProject, were created to consolidate conversations related to the project's topics. The consortium has been encouraged to use this hashtag in their social media communications.

5. Project leaflet

The EVH project leaflet has been produced by SVA. The brochure presenting the EVH project is shown in the figure below. Designed as a foldable 6-sided leaflet ready to be distributed in events, workshops and partnerships, the EVH leaflet provides comprehensive information on EVH's strategy, objectives, partners, and contact details. In order to convey information effectively across various digital platforms, it is easily accessible on the EVH website, and it has been shared with dedicated posts on the EVH social media.



The front side of the EVH project leaflet features a blue and white color scheme. At the top left is the EVH logo (European Vaccines Hub). To its right is a disclaimer: "Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them". Below this is the European Union flag and the text "Co-funded by the European Union". On the right side is another EVH logo. The central text reads "EUROPEAN VACCINES HUB FOR PANDEMIC READINESS". Below this, the website "Web site: europeanvaccineshub.eu" and social media links for LinkedIn and Twitter are provided, along with the email "Email: evhproject@sclavo.org". On the left side, under the heading "EVH KEY ACTIVITIES", a list of activities is provided:

- Develop and implement a **pandemic vaccines readiness plan** for Europe
- Develop **pandemic vaccine candidates** for agreed pathogens **up to Phase 2 clinical trials**, including through relevant in vitro and in vivo models.
- Organise and optimise the **clinical evaluation of candidate vaccines** including in Phases I and II and the appropriate and supportive use of controlled infection facilities to speed up clinical development.
- Ensure **rapid delivery** of vaccine candidates for trial and mass production to manufacturing partners
- Set up shared, ready-to-use and scalable state-of-the-art technology platforms covering all phases of vaccine development with a focus on high-yield and rapidly adaptable production systems.
- Prepare and support technology transfers among EU partners and other eligible entities as part of the **creation of a centre of shared knowledge** for pandemic-relevant vaccine development.
- Prepare and perform **stress tests of pandemic vaccine production**, including on critical supply-chain element
- Prepare relevant **master clinical trial protocols** combining its activities to reach out to clinical trial capacities/networks and at scale production initiatives at national and European levels
- Implement a **pandemic planning platform** operating in the most cost-effective way



The back side of the EVH project leaflet provides detailed information about the project's scope, strategy, and partners. It includes a diagram of the EVH structure, a list of EVH facts, and a comprehensive list of partners and affiliated entities.

EVH PROJECT

The project has the scope to provide EU with a self sustainable and independent ability to discover, develop and manufacture vaccines and monoclonal antibodies against infectious diseases of epidemic and pandemic potential.

The EVH project contributes to the development of an agreed set of pandemic-prototype vaccines and scalable technologies through a consortium of major EU Vaccine R&D institutions and manufacturers, ensuring effective coordination of national vaccine research programs. EVH aligns with the current international consensus on pandemic-vaccine development, leveraging insights from existing prototypes to enable the rapid selection and deployment of the most suitable vaccine candidates in an emerging pandemic.

EVH aims thus not only to create a reactive R&D system and knowledge hub linking powerful leading research institutions, but also initiate vaccine-development projects, refining relevant processes and procedures within its framework. The focus is on a select group of pathogens deemed critical for pandemic preparedness. From prototype design to clinical applications, the EVH drives innovation, enhance clinical evaluation capacities, and coordinate efforts with manufacturers while optimizing the digitalization of vaccine design and distribution processes.

EVH STRATEGY

EVH is organised around 4 Pillars, each supporting key activities and infrastructures of the vaccine development pipeline:

- Pillar 1 – **Discovery**, led by FBS
- Pillar 2 – **Pre-clinical Studies**, led by IP
- Pillar 3 – **Clinical Studies**, led by Vaccinopolis
- Pillar 4 – **Manufacturing & Regulation**, led by DZIF & ZEPAL

In the event of pandemic, each pillar will set up and implement the platform necessary for rapid vaccine development. EVH will engage and reinforce the complete ecosystem of European industry and academia, promoting collaborations and the exchange of know-how and projects.

EVH PARTNERSHIP

Beneficiaries:

- **SCLAVO** Sclavo Vaccines Association - SVA (IT)
- **FBS** Fondazione Biotechnologica di Siena - FBS (IT)
- **INSTITUT Pasteur** Institut Pasteur - IP (FR)
- **University of Antwerp** Universiteit Antwerpen - Vaccinopolis (BE)
- **DZIF** Deutsches Zentrum für Infektionsforschung - DZIF (DE)
- **Paul Ehrlich-Institut** Bundesinstitut für Impfstoffe und Biomedizinische Arzneimittel - ZEPAL (DE)
- **LUMC** Academic Medical Center - Academisch Ziekenhuis Leiden - LUMC (NL)
- **ULB** Université Libre de Bruxelles - ULB (BE)
- **NIPH** Norwegian Institute of Public Health - NIPH (NO)
- **UNISI** Università degli Studi di Siena - UNISI (IT)
- **IBET** Instituto de Biología Experimental e Tecnológica - IBET (PT)

Affiliated Entities:

- **Fondazione Biotechnologica di Siena:**
 - Istituto Zooprofilattico Sperimentale delle Venezie (IT)
- **Institut Pasteur:**
 - Infrastructure Nationale en Biologie et Santé-Commissariat à l'énergie atomique et aux énergies alternatives (FR)
 - Institut national de la santé et de la recherche médicale (FR)
- **Deutsches Zentrum für Infektionsforschung:**
 - Philipps Universität Marburg (DE)
 - Helmholtz Zentrum München (DE)
 - Helmholtz Centre for Infection Research (DE)
 - Ludwig-maximilians-Universität München (DE)
 - Stiftung Teirärztliche Hochschule Hannover (DE)
 - Technische Universität München (DE)
 - Universitätsklinikum Köln Aor (DE)
 - Universitätsklinikum Hamburg Eppendorf (DE)
 - Eberhard Karls Universität Tübingen (DE)

Associated partner:

- Pasteur Network (FR) (IP Associated partner)

Others:

- VisMederi s.r.l. (IT) (FBS Subcontractor)
- Reithera s.r.l. (IT) (FBS Subcontractor)

6. Conclusion

The communication of EVH project in the participant websites, social media and project leaflet have been described in this report. The Deliverable D2.1 “Presentation of EVH project in the Participant websites and social media” is achieved with the submission of this report.

Document review / approval (the coordinator)

Name	Role	Action (review / approval)	Date
Donata Medaglini	Scientific Project Coordinator	Review and Approval	25 June 2025